Label and source
The shipment should make the medication identity easy to verify
The first check is whether the product in the box matches the prescription decision. Patients should be able to identify the active ingredient, route, strength or format, patient name when applicable, dispensing pharmacy or branded channel, storage instructions, expiration or beyond-use date, and who to contact with questions. Compounded prescriptions should not be described as FDA-approved finished drug products.
- GLP-1 and GIP/GLP-1 shipments may involve branded pens, compounded prescriptions, cold-chain packaging, supplies, and side-effect instructions that should be product-specific.
- Sermorelin, PT-141/bremelanotide, glutathione, NAD+, GHK-Cu topical foam, and methylene blue differ by route, label details, storage, and follow-up needs; one product’s instructions should not be transferred to another.
- No-prescription sellers, research-use vials marketed for human results, vague labels, hidden pharmacy sourcing, or generic dose charts are care-quality red flags.